EYPT JPM2026 Presentation_vF.pdf

1、 2026 EyePoint.All Rights Reserved.J.P.Morgan Healthcare Conference PresentationJanuary 13,2026Jay S.Duker,M.D.President and CEO 2026 EyePoint.All Rights Reserved.2Legal DisclaimersVarious statements made in this presentation are forward-looking,within the meaning of the U.S.Private Securities Litig

2、ation Reform Act of 1995,and are inherently subject to risks,uncertainties and potentially inaccurate assumptions.All statements that address activities,events or developments that we intend,expect,plan or believe may occur in the future,are forward-looking statements,including but not limited to st

3、atements regarding:our expectations regarding our clinical development and regulatory plans;our belief that DURAVYUis on track to be the first-to-market of the current investigational sustained release treatments for wet AMD;our belief that DURAVYU has two potential blockbuster indications;our belie

4、f that DURAVYU is the only TKI in development for DME;our belief that DURAVYU is uniquely positioned to potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME as a sustained delivery therapy;our belief that DURAVYUs potential real-world application in m

5、ultiple retinal disease indications and de-risked trial designs position DURAVYU for clinical and commercial success;our expectations regarding timing for commencement of DME clinical trial enrollment and the timing of the availability and release of wet AMD clinical data;our expected cash runway;ou

6、r belief that DURAVYU has the potential to maintain a majority of patients with active disease with no supplemental anti-VEGF therapy for six months or longer;our expectations regarding our manufacturing capabilities;and our expectations regarding the timing and clinical development of our other pro